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Abstract
Muscle relaxation is triggered by the dephosphorylation of Ser19 in the myosin regulatory light
chain. This reaction is catalyzed by the holoenzyme myosin phosphatase (MP), which includes the
catalytic subunit protein phosphatase 1 (PP1) and the regulatory targeting subunit (MYPT).
MYPT1 (myosin phosphatase targeting subunit 1) is responsible for both targeting the
holoenzyme to subcellular compartments in the muscle and directing PP1 specificity towards
myosin. In order to understand the molecular events leading to the MYPT1:PP1 holoenzyme
formation, we used NMR spectroscopy to determine the structural and dynamic characteristics of
unbound MYPT1. This allowed the conformations of MYPT1 in the free, unbound state to be
directly compared to the PP1-bound state. Our results show that MYPT11-98 behaves like a two-
domain protein in solution. The first 40 residues of MYPT11-98, the disordered region, are
intrinsically disordered and highly dynamic, whereas residues 41–98, the folded ankyrin-repeat
region, are well-structured and rigid. Furthermore, the integrated use of NMR and biophysical data
enabled us to calculate an ensemble model for MYPT11-98. The most prominent structural feature
of the MYPT11-98 ensemble is a 25% populated transient α-helix in the disordered region of
MYPT11-98. This α-helix becomes fully populated when bound to PP1 and, as we show, likely
plays a central role in the formation of the MYPT1:PP1 holoenzyme complex. Finally, this
combined analysis shows that the structural and dynamic behaviors exhibited by MYPT1 for PP1
are distinct from those of any other previously analyzed PP1 regulatory protein. Collectively, these
data enable us to present a new model of the molecular events that drive MYPT1:PP1 holoenzyme
formation and demonstrate that there are structural differences in unbound PP1 regulators that
have not been previously observed. Thus this work adds significant insights to the currently
limited data for molecular structures and dynamics of PP1 regulators.
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Phosphorylation of myosin II regulates smooth muscle contraction, cell motility and
cytokinesis, among many other essential biological functions1,2. The responsible kinase is
myosin light chain kinase, with myosin phosphatase (MP) identified as the counterpart
phosphatase. The core enzyme of MP is Protein Phosphatase 1 (PP1), the most widely
expressed and abundant Ser/Thr phosphatase, which is responsible for a large number of
dephosphorylation reactions in humans. PP1 is a single domain enzyme (3 isoforms: α, β/δ,
(two splicing products: γ1 and γ2); ~330 residues) that is exceptionally well conserved, from
fungi to human, in both sequence and function3.
The catalytic site of PP1 contains two metal ions and is at the intersection of three putative
substrate binding regions, referred to as the hydrophobic, acidic and C-terminal grooves3.
The specificity of apo-PP1 is low. Nevertheless, in vivo, PP1 is able to dephosphorylate its
substrates with high specificity. To achieve this specificity, PP1 interacts with a large
number of regulatory proteins (~200 confirmed interactors)4–6. Targeting proteins bind PP1
and direct its specificity by localizing PP1 to its point of action within the cell, as well as by
directly altering its substrate preferences7, while inhibitor proteins directly inhibit the
phosphatase activity of PP1. Most PP1 regulatory proteins (≥95%) contain a primary PP1
binding motif [R/K][R/K][V/I]x[F/W], commonly referred to as the RVxF motif, which
interacts with a binding region more than 20 Å away from the active site of PP18,9. It has
become clear that this interaction is critical for the formation of a stable complex; however
the RVxF motif itself does not play a major role in influencing the substrate specificity of
PP1.
Only a very limited number of PP1 holoenzyme structures are currently available7,10,11. The
difficulty for structure determination of PP1 holoenzymes arises primarily from two factors:
the instability of apo-PP1 in solution12 and the high flexibility of most PP1 regulatory
proteins13. Only a single structure of an inhibitor:PP1 (inhibitor-2:PP110,14) and three
targeting protein:PP1 (MYPT1:PP111, spinophilin:PP1 and neurabin:PP17) complexes have
been reported. Recently, we have probed the structural properties of unbound PP1 regulatory
proteins in significant detail. Inhibitor-2 (I-2), DARPP-32 and the PP1-binding domain of
spinophilin are all intrinsically disordered in their unbound states7,13. Ensemble modeling of
these intrinsically disordered proteins, using large sets of experimental restraints, revealed
diverse structural properties with both spinophilin and I-2 having partially formed α-helices
(~25% populated for spinophilin, ~80% for I-2) that directly correspond to α-helices in their
bound-state crystal structures14. Strikingly, spinophilin becomes completely ordered upon
binding to PP1, while I-2 remains substantially disordered (~70%) in its PP1-bound state.
Finally, diverse propensities for transient tertiary structure were observed, especially in
spinophilin and I-2, which possess significant long-range contacts that are likely key for
their biological functions.
The specificity of MP is primarily determined by the interaction of PP1 with the targeting
protein MYPT (myosin phosphatase targeting subunit). Furthermore, a second protein, M20,
can interact with MYPT, yet the function of M20 is currently unknown. The MYPT family
comprises five members: MYPT1, MYPT2, MBS85, MYPT3 and TIMAP (ranked by
degree of sequence identity with MYPT1). MYPT1 (myosin phosphatase targeting subunit
1), which is the most highly expressed subunit in smooth muscle cells, is a 110 kDa protein
(residues 1-1030) that interacts with PP1δ to form the MP holoenzyme. The crystal structure
of the MYPT1 (residues 1-299):PP1 complex has been reported11 (Figure 1A,B). In
agreement with earlier reports, the N-terminal 40 residues of MYPT1 are critical for the
interaction with PP111,15; however, additional MYPT1 regions, including the C-terminal
ankyrin-repeats, contribute to PP1 binding. Thus, to gain information on the formation of the
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MP complex, we used numerous biophysical and computational tools to determine the
structural and dynamical characteristics of the unbound MYPT1 domain that are essential
for PP1 regulation. We found that unbound MYPT1 can be split into two structurally distinct
regions: the N-terminal 40 residues are intrinsically disordered (disordered region), while
the rest of the protein remains folded in a conformation similar to that observed in the
crystal structure (folded ankyrin-repeat region). The intrinsically disordered region contains
a partially populated α-helix that corresponds perfectly to an α-helix that forms upon PP1
binding, as well as a locally extended region that corresponds to the functionally important
RVxF motif. Finally, we integrate the various experimental measurements into an ensemble
model calculation of partially disordered, partially folded MYPT1, similar to those
performed previously for I-2, DARPP-32 and spinophilin. These calculations enable a
detailed structural representation of the unbound state and further expand our knowledge of
how these intrinsically disordered PP1 regulatory proteins direct PP1 activity.
Methods and Materials
Protein expression and purification
MYPT1 constructs 1-299, 1-98, and 1-41 (Figure 1) were subcloned into an in-house
modified pET-28a vector (RP1B), which encodes a Thio6His6 expression/purification tag
and a TEV protease cleavage site16. Wt-MYPT1 (amino acid construct residues 1-98) has a
tendency to rapidly form dimers in solution, which can be reversed by the addition of large
quantities of reducing reagent, such as DTT or TCEP. Mutation of Cys81 to Ser was
introduced to circumvent dimerization of this construct. Interestingly, Cys47 does not have
an effect on dimerization and thus was not mutated. Thus, all experiments conducted with
MYPT1 construct 1-98 were performed using the mutant C81S, which is subsequently
referred to as MYPT11-98. The plasmids were transformed into Escherichia coli strain
BL21-Codon-Plus (DE3)-RIL (Stratagene). The expression of uniformly 15N- and 15N/13C -
labeled proteins was carried out by growing freshly transformed cells in M9 minimal
medium containing 1 g/L 15NH4Cl and/or 4 g/L [13C]-D-glucose (CIL) as the sole nitrogen
and carbon sources, respectively. Cells were grown at 37°C under vigorous shaking (250
rpm) in the presence of 34 μg/mL chloramphenicol and 50 μg/mL kanamycin until they
reached an OD600 of 0.6–0.8. Expression of His6-MYPT1 constructs was induced by
addition of 1 mM β-D-thiogalactopyranoside (IPTG) to the culture medium, and cultures
were allowed to grow overnight (18 h) at 18°C under vigorous shaking (250 rpm). Cells
were harvested by centrifugation and stored at −80°C.
The purification of all three MYPT1 constructs (1-299, 1-98, and 1-41) was performed as
follows. Cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5 mM
imidazole, 0.1 % Triton-X 100, supplemented with EDTA-free protease inhibitor tablets
(Roche)) and lysed by high-pressure homogenization (Avestin C-3 Emulsiflex). Cell debris
was removed by centrifugation at 35000 × g for 40 minutes at 4°C, and the supernatant
containing soluble proteins was loaded onto a HisTrap HP column (GE Healthcare)
equilibrated with 50 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole. His6-MYPT1
constructs were eluted with a 5–500 mM imidazole gradient. Fractions containing the
protein of interest, as identified by SDS-PAGE gel electrophoresis, were pooled, incubated
with His6-TEV NIa (S219V) protease (in-house produced), and dialyzed against 50 mM Tris
pH 7.5, 200 mM NaCl, until cleavage was complete. The untagged proteins were separated
from the enzymatically-cleaved His6 tag as well as from His6-TEV by a Ni+2-affinity
subtraction purification step using Ni-NTA beads (Qiagen). The proteins were subsequently
purified by size-exclusion chromatography using a Superdex 75 26/60 column (GE
Healthcare) equilibrated with 20 mM sodium phosphate pH 6.8, 50 mM NaCl, 0.5 mM
TCEP. Fractions containing the pure proteins, as identified by SDS-PAGE, were pooled and
concentrated. All purifications were performed at 4°C. Phenylmethanesulfonyl fluoride
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(PMSF), at a final concentration of 0.25 mM, and 10% D2O were added to the final samples
used for NMR measurements.
NMR measurements
All NMR experiments were acquired at 278 K (lowest stable temperature for cryoprobe used
on our system) on a Bruker AvanceII 500 MHz spectrometer equipped with a TCI HCN-z
cryoprobe. Proton chemical shifts were referenced directly to internal 3-trimethyl-sylil-1-
propanesulfonic acid, sodium salt (DSS). 13C and 15N chemical shifts were referenced
indirectly to DSS using the absolute frequency ratios.
Chemical Shift Assignment
The following spectra were used to achieve the sequence-specific backbone resonance
assignments of MYPT11-98: 2D 1H-15N HSQC, 3D HNCA, 3D HNCACB, 3D
CBCA(CO)NH, 3D HNCO, 3D HN(CA)CO, 3D CC(CO)NH, 3D HBHA(CO)NH17.
TopSpin 1.3 (Bruker) was used for data acquisition and processing. NMR spectra were
analyzed with CARA (www.nmr.ch). Chemical shift assignments of MYPT11-98 were
deposited in the BMRB data base (www.bmrb.wisc.edu) as entry 16160.
Secondary Structure Propensity
Secondary structure propensity (SSP) scores18 were calculated for MYPT11-98 using the
RefDB19 random coil data base. A seven-residue moving-average window size, which
excludes experimental data from residues before prolines, was used in the calculation.
Relaxation measurements
15N longitudinal (R1) and transverse (R2) relaxation rates and [1H]-15N heteronuclear NOEs
were measured as described previously20. All spectra were performed with 2048 × 256
complex data points. The sweep widths of the 1H and 15N dimensions were set to 12 and 26
ppm, respectively. T1 experiments were acquired with relaxation delays (T) of 20, 100, 200,
300, 450, 600, 750, and 1000 ms. T2 experiments were acquired with relaxation delays (T)
of 20, 50, 100, 150, 200, 275, 350, and 450 ms. A recycle delay of 3 s between scans was
used for all T1 and T2 experiments. [1H]-15N NOEs were measured from a pair of spectra
acquired with and without presaturation recorded in an interleaved manner. A recycle delay
of 5 s between scans was used for NOE experiments.
Relaxation Data Analysis
All spectra were processed with NMRPipe version 97.027.12.5621 and analyzed with
NMRView version 5.2.2.0122. R1 and R2 relaxation rates were determined by fitting the
peak intensities as a function of the relaxation delays using a two-parameter
monoexponential decay function, I(T) = I0exp(−R1,2/T), where I(T) is the peak intensity
after a time delay T and I0 is the intensity at time zero. [1H]-15N NOEs were calculated by
dividing the intensity of the peaks in the spectra recorded without presaturation by the
intensity of the peaks in the presaturated spectra.
Residual Dipolar Couplings
RDC measurements were performed with a 0.5 mM MYPT11-98 sample aligned in 5% (wt/
vol) n-octyl-penta(ethylene glycol)/1-octanol (C8E5) (Sigma) dissolved in 20 mM sodium
phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP23. N–H RDCs (DNH) were determined
using the IPAP 15N-HSQC sequence24,25. All spectra were performed with 2048 × 1024
complex data points. DNH values were calculated as the difference between DNH+JNH
measured in an aligned sample and JNH measured in an isotropic sample. RDC analysis was
performed using the program DIPOCOUP26. RDC calculations/predictions within the
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ENSEMBLE calculations were performed using the program PALES27. Direct comparison
of RDCs measured for unbound MYPT11-98 with best-fit (calculated) RDCs for MYPT11-98
taken from the MYPT1:PP1 crystal structure is, as expected, not ideal, but show the
anticipated measure of agreement.
Circular Dichroism Spectroscopy
Far-UV circular dichroism (CD) measurements were recorded using a Jasco J-815
spectropolarimeter, in a 2 mm optical path quartz cell (Hellma), using either a 5 μM
MYPT11-299 or a 10 μM MYPT11-98 sample (20 mM Na-phosphate pH 6.8, 50 mM NaCl,
0.5 mM TCEP) at 4°C. All spectra were acquired from 260 to 195 nm, with a scan speed of
50 nm/min, 5 accumulations and a response time of 2 s. Equivalent spectra of buffers were
recorded and subtracted from the protein spectra. Thermal denaturation experiments were
performed at 220 nm with a temperature ramp of 1°C/min that was established using a
Peltier temperature control unit.
Dynamic Light Scattering
DLS measurements were performed with a 100 μM MYPT11-98 sample (20 mM Na-
phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP) using a Viscotek model 802 dynamic light
scattering instrument at 4°C. The hydrodynamic radius (Rh) of MYPT11-98 was calculated
using the Viscotek measurement software. All DLS measurements were performed
immediately following elution of MYPT1 from a SEC column to ensure that no soluble
aggregates or impurities interfere with the measurements.
MYPT1-PP1 complex formation
PP1α production was described previously12. Escherichia coli strain BL21 (DE3)
(Invitrogen) cells expressing His6-PP1α1-330 were resuspended in lysis buffer (50 mM Tris
pH 8.0, 700 mM NaCl, 5 mM imidazole, 1 mM MnCl2, 0.1 % Triton-X 100, supplemented
with EDTA-free protease inhibitor tablets (Roche)) and lysed by high-pressure
homogenization (Avestin Emulsiflex C-3). Cell debris was removed by centrifugation at
97000 × g for 40 minutes at 4°C, and the supernatant containing His6-PP1α1-330 was loaded
onto Ni-NTA beads (Qiagen) equilibrated with buffer A (50 mM Tris pH 8.0, 700 mM
NaCl, 5 mM imidazole, 1 mM MnCl2). The beads were washed with low salt buffer A (50
mM Tris pH 8.0, 50 mM NaCl, 5 mM imidazole, 1 mM MnCl2) and consequently incubated
with purified MYPT11-98 for 1 h at 4°C under slow shaking in order to allow for binding.
MYPT11-98 co-eluted with His6-PP1α1-330 from the Ni-NTA beads upon wash with buffer B
(50 mM Tris pH 8.0, 50 mM NaCl, 500 mM imidazole, 1 mM MnCl2). Since only
PP1α1-330 was his-tagged, co-elution of both proteins confirms that MYPT11-98 forms a
complex with PP1α1-330, indicating a strong interaction, as previously detected for PP1
targeting protein complexes7,28,29.
Calculation of MYPT1 ensemble model
A model of unbound MYPT11-98 was calculated using the program ENSEMBLE30–32. The
folded ankyrin-repeat region (residues 41-98) was kept identical to the published crystal
structure, while the disordered N-terminal region (residues 1-40) was allowed to vary in
conformation. 13Cα, 13Cβ, 13C′, 1Hα, 1HN and 15N chemical shift restraints and 15N R2
restraints were applied to residues 1-40 (Table 1). The overall Rh was restrained for the full
protein. 15N-1H RDC restraints were used for the full protein. RDCs were restrained by
averaging the values calculated using independent global alignment of each conformer with
the program PALES27. Note that this differs from the local alignment approach used
previously33 because the model calculated here contains both a folded and a disordered
region. Thus both folded and disordered regions contribute to the alignment of each
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molecule. Six independent ensembles were calculated using the simplest ensemble
approach32, in which ensembles with the fewest number of structures that fit all of the
experimental restraints are calculated. Each of the six final ensembles contained between
21–27 structures. Cluster analysis was performed using the NMRClust algorithm34 and the
distance matrix root mean square deviation.
A “statistical coil model” of MYPT11-98 was created by the program TraDES35 to generate
random structures for the N-terminal residues 1-40 using the ‘Coil’ sampling distribution33.
These structures were coupled with residues 41-98 from the crystal structure. Resulting
models with steric clashes were discarded. A total of 5000 structures without steric clashes
were generated.
Results
Three MYPT1 constructs (Figure 1), MYPT11-299 (identical to the construct used for crystal
structure determination), MYPT11-98 and MYPT11-41 (disordered region) were expressed in
E. coli and purified to homogeneity. Stability and folding of these MYPT1 fragments were
determined using CD spectropolarimetry. As expected, MYPT11-299 shows a CD spectrum
typical of a well-folded α-helical protein with a melting temperature of 48 ± 2°C
(Supplemental Figure S1A). MYPT11-98 has a similar CD spectrum at low temperature
(melting temperature of MYPT11-98 was determined to be 25 ± 2°C) (Supplemental Figure
S1B). Based on the melting temperature results, all NMR-based studies with MYPT11-98
were performed at 5°C, DLS measurements were performed at 4°C. Complex formation of
MYPT11-98 with PP1 was used as a functional assay to ensure that biologically relevant,
active protein constructs were used in this study (Supplemental Figure S2). Lastly, it was
previously shown that an MYPT1 peptide (residues 1-38) binds PP1 with a Kd of ~45 nM15.
Taken together, MYPT11-98 was chosen for further detailed studies as it shares many of the
characteristics of MYPT11-299, including both a disordered region and a folded ankyrin
repeat region, yet is very well-suited for high-quality NMR studies.
MYPT11-98 contains a folded and an intrinsically disordered region
Using heteronuclear multidimensional NMR spectroscopy, the sequence-specific chemical
shift assignment of MYPT11-98 was completed (Supplemental Figure S3). Using the
chemical shift-derived SSP analysis and fast time-scale 15N auto-correlated relaxation
measurements, it became evident that MYPT11-98 behaves like a two-domain protein in
solution (Figure 1&2). MYPT1 residues 1-40 form the disordered region, while MYPT1
residues 41-98 form the folded ankyrin-repeat region.
To further verify the two-region behavior of MYPT11-98, we produced MYPT11-41. By
directly overlapping the 2D [1H,15N] HSQC spectra of MYPT11-98 and MYPT11-41 it is
readily evident that the NH cross-peaks of MYPT11-41 overlap well with the NH cross-
peaks of amino acids 1-41 in the MYPT11-98 spectrum (Supplemental Figure S4). This
shows that minimal interaction between the PP1-binding and the ankyrin-repeat domain of
MYPT11-98 are expected in the unbound form.
Fractional secondary structure in the intrinsically disordered region
Our NMR data shows that in solution the free PP1-binding domain of MYPT1 has an
intrinsically disordered region. However, it is possible to identify preferential secondary
structure in this disordered region using SSP analysis (Figure 2A). First, MYPT1 residues
5-17 form a ~25% populated α-helix. Interestingly, these residues fold into a fully populated
α-helix when bound to PP111. Furthermore, this helix has been previously identified to
contain a PP1 consensus binding sequence (R-X-X-Q-[V/I/L]-[K/R]-X-[Y/W], where x can
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be any residue), which is referred to as the myosin phosphatase N-terminal element or
MyPhoNE5. As this sequence is also present in six other unrelated PP1 targeting proteins, it
is likely that it plays a role in PP1 substrate selection. Second, residues 31-38 preferably
populate the β-region of ϕ/ψ-conformational space. Residues 31-38 include residues 35
KVKF38, the MYPT1 RVxF motif, the essential PP1 anchoring motif that is shared by
>95% of all PP1 regulators. This is significant, as in all currently available structures the
RXvF motif binds in an extended fashion into the PP1 RVxF binding groove. Collectively,
these data show that it is possible to identify two regions in the disordered region that
exhibit preferred ϕ/ψ-space populations. Interestingly, both regions play a role in the
formation of the PP1:MYPT1 holoenzyme and, based on our analysis of the structure of
unbound MYPT1, seem to be primed for rapid complex formation. Therefore, providing the
binding on-rates exceed the rates of interconversion between different MYPT1
conformations, MYPT1 most likely binds to PP1 through a conformational selection
mechanism.
Preferred conformations and restricted dynamics
To gain additional insights into MYPT1’s preferred transient structure, auto-correlated 15N
R1, R2 and 15N[1H]-NOE relaxation data were recorded (Figure 2B,C and Supplemental
Figure S5). The interpretation of relaxation rates in highly flexible proteins, such as the
disordered region of MYPT1, is different from that in structured proteins because internal
motions in structured proteins occur on a different time scale from that of the overall
tumbling motion of the protein. Thus, there is an obvious difficulty in differentiating
“internal” and “overall tumbling” motion in disordered proteins. Consequently, we focus on
the qualitative analysis of R2 values since they are especially sensitive to local structure
variations.
The average R2 rate for the flexible N-terminal disordered region is 8.4±1.8 Hz, while it is
17.8±2.2 Hz for the folded ankyrin-repeat region, again highlighting the two-domain
behavior, as already described above. Reduced flexibility can be identified in the ~25%
populated N-terminal helix. Interestingly, and in difference with other studied PP1
regulatory proteins7,13, the 15N[1H] NOE is positive throughout the sequence.
Conformational sampling of the MYPT1 PP1-binding domain
Dynamic light scattering (DLS) reports a hydrodynamic radius of 20.7 Å for MYPT11-98.
This radius corresponds to a globally folded protein with a molecular weight of ~18 kDa,
which is ~7 kDa larger than expected, providing additional evidence of the extended
behavior of the N-terminal disordered region. Furthermore, while i,i+1 1HN-1HN NOE
cross-peaks, typical for α-helical secondary structure elements, can be detected in the well-
folded ankyrin-repeat region (residues 41-98) of MYPT11-98, no significant i,i+1 1HN-1HN
NOE cross-peaks are identified in the disordered region (residues 1-40).
Paramagnetic relaxation enhancement data are typically used to extract distance constraints
for flexible protein regions. Paramagnetic spin-labels, such as the commonly used MTSL
label, are attached to a free cysteine residue. MYPT11-98 contains a single cysteine residue
at position 47 (the only other Cys in MYPT1, Cys81, had already been mutated to a Ser to
prevent dimerization, see methods). However, MTSL spin-labeling of Cys47, as well as
mutation of Cys47 to Ser, led to unfolding of the folded ankyrin-repeat region
(Supplemental Figure S6). Mutation of other residues to cysteine in MYPT11-98 was
possible (A6C and S20C). However, S20C did not express. A6C did express at a much
lower level then MYPT11-98. MTSL spin-labeling led to an apparent mixture of labeled
residues and/or additional conformations (based on significant chemical shift changes and
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additional peaks in the 2D [1H,15N] HSQC spectrum, Supplemental Figure S7), which
makes the extraction of useful information impossible and thus was not pursued.
In order to provide additional structural insights, we probed the relative orientation of the
two regions in MYPT11-98 by measuring residual dipolar couplings (RDCs) using a 5%
C8E5/1-Octanol alignment medium (alignment tensor: Dax=7.99 Hz and Rh=0.41) (Figure
3A). In the folded ankyrin-repeat region, the RDCs show a good correspondence with the
ankyrin-repeat α-helices. In the disordered region, RDCs are primarily negative, with a peak
closely matching the ~25% populated N-terminal α-helix, consistent with previous results
showing a strong correlation between RDCs and secondary structure33,36. In addition, there
are strong negative RDCs for residues 23-40, which includes the RVxF motif (35 KVKF38),
suggesting a significant deviation from random-coil behavior in this region, likely due to
extended backbone conformations and/or the formation of tertiary contacts.
We compared our experimental RDCs to those calculated from MYPT11-98 taken from the
MYPT1:PP1 crystal structure. In this case the N-terminal disordered region is folded into its
complex-bound conformation (Figure 3B). Importantly, the experimental and calculated
RDCs agree well for residues in the folded ankyrin-repeat region suggesting it adopts a
similar structure in solution as in the crystal structure (Q-factor37=0.51 for MYPT1 residues
41-98). The differences between the experimental and calculated RDCs are largest for
residues 23-40, indicating that these residues adopt a different conformation when unbound
in solution than they do when complexed to PP1. This is confirmed by a Q-factor analysis37
for MYPT1 residues 1-40 where the Q-factor drastically increases to 0.90, and thus confirms
that the N-terminal disordered region adopts a different overall conformation(s) in the free
form, when compared to the crystal structure-based bound conformation.
Ensemble model of unbound MYPT11-98
To further understand the structure of unbound MYPT1 and to advance our insight into the
interaction with PP1, ensemble models of unbound MYPT11-98 were calculated using the
program ENSEMBLE. In the calculations of these models, the structure of the folded
ankyrin-repeat region was kept identical to that in the crystal structure, while the N-terminal
disordered region (residues 1-40) were allowed to adopt varying conformations,
representative of its disordered nature. Six independent ensemble models were calculated
using identical experimental restraints and parameters and the model presented below
represents the combination of all six ensembles. Table 1 presents the agreement between
experimental measurements and ensemble calculated properties.
The residue-specific secondary structure content of the ensembles, including the fraction of
residues within the broad α, left-β and right-β regions of Ramachandran space (previously
defined32) and the fraction of residues identified as α-helical by STRIDE38 are presented in
Figure 4A. The most notable secondary structure element observed is a ~25% populated α-
helix in the N-terminal disordered region of MYPT1, similar to that seen from chemical shift
analysis (Figure 2A). This helix becomes 100% populated in the MYPT1:PP1 holoenzyme
structure.
To further assess the quality of the ensemble calculation, the experimental and ensemble-
calculated RDCs were compared (Figure 4B). This figure also shows a comparison of the
experimental RDCs to those predicted for a 5000-structure “statistical coil model”, which
was created by combining the folded ankyrin-repeat region structure with TraDES ‘Coil’
model35 conformers representing the N-terminal disordered region. Conformers that led to
steric clashes were removed. Clearly, the ensembles are highly consistent with the
experimental RDCs for the N-terminal disordered region and also show good agreement
with the folded ankyrin-repeat region of MYPT11-98. The poorer agreement of folded-region
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RDCs in the statistical coil model relative to the calculated ensemble model (despite the fact
that the structure of this region is identical), arises from the fact that, in the ENSEMBLE
calculations direct selection for agreement between ensemble-calculated and experimental
RDCs is used. Lastly, the deviation of the statistical coil model from the experimental RDCs
in the disordered region provides further evidence for the existence of substantial non-
random structure in this region.
MYPT1 ensemble cluster analysis
Contact plots are a useful way to observe tertiary structure in proteins. However, in a highly
dynamic and heterogeneous disordered-state ensemble, low populated contacts are often
difficult to identify. Therefore, it is most useful to divide the ensembles into clusters of
structurally similar conformers32. Tertiary structure analysis of each cluster, e.g. via tertiary
contacts plots, can be much easier and more reliably performed. Although the ENSEMBLE
calculations performed here did not include long-range NOE or PRE restraints that are
typically used for defining tertiary contacts, RDCs can also contain useful information on
tertiary structure, although their utility in this regard remains less defined39. Thus, while the
contact plots presented here provide hints as to the likely tertiary contacts in unbound
MYPT1, they should be regarded with much less certainty than the secondary structure
analysis.
Figure 5 shows the three highest populated clusters (A - 29%, B - 19%, C - 16%). In blue is
the folded ankyrin-repeat region (residues 39-98), red is residues 1-19 and green is residues
20-38. The associated fractional contact plots are shown below (ENSEMBLE clusters on the
top halves and the crystal structure on the bottom halves). Interestingly, all three clusters
show some tertiary contacts between the disordered region and the folded ankyrin-repeat
region, unlike MYPT11-98 in the crystal structure. The highest populated cluster shows a
tight bundle of structures of the N-terminal fractionally populated α-helix. The additional
clusters show less coherence and a much higher variance in the N-terminal α-helix. Taken
together, this analysis correlates well with our experimental comparison of the 2D [1H,15N]
HSQC spectrum of MYPT11-98 and MYPT11-41, where we detected only minimal
differences. Notably, residue 6 is involved in significant contacts in clusters 2 (with residues
15-30) and 3 (with residues 15-35, 49-52, 71-74 & 82-84), which is interesting as spin-
labeling of residue 6 led to the apparent formation of an alternate conformation in solution
(Supplemental Figure S7). Therefore, it is tempting to speculate that these structural changes
observed upon spin-labeling may be related to the disruption of contacts involving this
region.
Discussion
A great wealth of functional data describing the biological importance of PP1, PP1
holoenzymes as well as either targeting or inhibitor proteins is readily available. However,
information regarding their molecular structures is noticeably sparse. To date, all structurally
analyzed PP1 targeting and inhibitor proteins fall into the class of intrinsically disordered
proteins7,13,14,40–42. Indeed, recently we predicted that at least 60% of all experimentally
confirmed PP1 regulatory proteins are intrinsically disordered4. Previously, we and others
described the inhibitor protein inhibitor-2 (I-2) in its free form, using NMR, SAXS data
analysis and ensemble calculations, and its PP1-bound form, using NMR, SAXS data and X-
ray crystallography10,14. This analysis enabled us to detect a highly populated α-helix
(~80%) in unbound I-2, which, in the PP1-bound form becomes 100% populated and, most
significantly, blocks the PP1 active site. Interestingly, these residues in unbound I-2 have
fast ps/ns timescale motions that are typical for a well-folded protein, as detected
by 15N[1H]-NOE experiments. However, while significantly populated secondary structure
content seems to play a role in I-2:PP1 recognition, no significant tertiary contacts
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resembling the bound conformation were identified in the ensemble analysis. Interestingly,
Trp46, the aromatic residue in the I-2 RVxF motif, formed a locus for hydrophobic collapse
within unbound I-2, becoming partially buried rather than surface exposed and accessible for
PP1 interaction. Nevertheless, the ~80% populated α-helix was not involved in the collapse
and appears primed for interaction with PP1, emphasizing the importance of pre-populated
secondary structure for the I-2:PP1 interaction.
This was in contrast to our analysis of the highly dynamic PP1-binding domain of the PP1
targeting protein spinophilin (virtually all residues have negative 15N[1H]-NOE values).
While a relatively short, ~25% populated α-helix was identified in unbound spinophilin that
corresponded to a helix observed in the crystal structure, a significant β-strand-like tertiary
interaction was also detected. This is interesting, as residues in these β-strand regions form a
β-sheet in the PP1-bound conformation of spinophilin, which extends an existing β-sheet in
PP17. Another distinguishing feature is that, while I-2 remains significantly disordered and
only the helical elements become stabilized when in complex with PP1, spinophilin
completely folds upon binding to PP1.
Taken together, different structural parameters play key roles for the IDPs I-2 and
spinophilin in their interaction with PP1. Thus, it is of interest to compare them to structural
features of the unbound MYPT1 PP1-binding domain and their influence on its interaction
with PP1 (Figure 1). The most significant difference between I-2, spinophilin and the PP1-
binding domain of MYPT1 is the fact that the MYPT1 PP1-binding domain is not
completely intrinsically disordered. Rather, it behaves as a two-domain protein, with a
folded ankyrin-repeat region, which forms the structured core of MYPT1. As identified in
the MYPT1:PP1 complex structure, all ankyrin-repeats make interactions with PP1. In
contrast, the N-terminal 40 residues of MYPT1 are highly dynamic forming a disordered
region. However, 15N[1H]-NOE analysis showed that residues in the MYPT1 disordered
region are more restricted on the ps-ns timescale than residues in I-2 or spinophilin. This
two-domain behavior is likely true for the MYPT family of PP1-interacting proteins, based
on primary sequence comparison and IUPRED43 prediction of their PP1-binding domains
(Supporting Figure S8).
Interestingly, the disordered region contains two MYPT1:PP1 interaction hallmarks: 1) the
N-terminal MyPhoNE motif and 2) the RVxF PP1 binding motif5. As we observed using
chemical shift analysis, both interaction motifs show a conformational bias towards their
respective PP1-bound forms and most likely function as interaction anchors, potentially in a
manner described in the theoretical “fly-casting mode” of protein:protein interaction44. The
increased flexibility of the disordered region of MYPT1 PP1-binding domain likely
enhances its capture radius, possibly facilitating the molecular recognition of PP1.
Conversely, the preformed transient structure in the disordered region of MYPT1
contributes to the specificity of its interaction with PP1, as well as possibly decreases the
entropic penalty associated with the binding of intrinsically disordered proteins to their
molecular targets.
Based on our data for the MYPT1 binding domain, we speculate on a kinetic model for the
interaction of MYPT1 with PP1. It is well recognized that the RVxF motif interaction is a
very strong, hydrophobic interaction that plays a significant role in the interaction of PP1-
regulators with PP1. Indeed, the RVxF site:PP1 interaction increases the stability of PP145.
Conversely, the MyPhoNE motif interaction contains both hydrophobic and electrostatic
interaction residues: MYPT1 residues L14, W17 form hydrophobic interactions, while
MYPT1 residues R10, Q13, R16 form electrostatic interactions. As electrostatic interactions
are long-range and are often involved in the initiation of binding, it is possible that the
electrostatic interactions formed by residues in the MyPhoNE helix create the initial
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interaction site for the MYPT1:PP1 interaction, with the RVxF motif site forming a tight
hydrophobic lock. While it is also possible that the stronger interaction of the RVxF motif
leads to a faster binding on-rate, the MyPhoNE motif is more distant from the folded
ankyrin-repeat region, possibly enlarging the capture radius of MYPT1 for PP1. This model
correlates well with a previously SPR-detected biphasic interaction of MYPT11-3815. These
distinct interaction sites may provide a more effective, faster “fly-casting”, as two rather
than a single binding site are available to “reel in” PP1. Finally, our work highlights
differences between unbound PP1 regulators, significantly adding to the very limited
knowledge of the molecular structures and dynamics of PP1 regulators.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Dr. R. Dominguez for generously providing the MYPT1 plasmid. This work was supported by NIH
(R01NS056128) to WP and the Canadian Institutes of Health Research to JDFK.
References
1. Ito M, Nakano T, Erdodi F, Hartshorne DJ. Mol Cell Biochem. 2004; 259:197–209. [PubMed:
15124925]
2. Matsumura F, Hartshorne DJ. Biochem Biophys Res Commun. 2008; 369:149–56. [PubMed:
18155661]
3. Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, Kuriyan J. Nature. 1995; 376:745–53.
[PubMed: 7651533]
4. Bollen M, Peti W, Ragusa MJ, Beullens M. Trends Biochem Sci. 2010; 35:450–458. [PubMed:
20399103]
5. Hendrickx A, Beullens M, Ceulemans H, Den Abt T, Van Eynde A, Nicolaescu E, Lesage B, Bollen
M. Chem Biol. 2009; 16:365–71. [PubMed: 19389623]
6. Meiselbach H, Sticht H, Enz R. Chem Biol. 2006; 13:49–59. [PubMed: 16426971]
7. Ragusa MJ, Dancheck B, Critton DA, Nairn AC, Page R, Peti W. Nat Struct Mol Biol. 2010;
17:459–64. [PubMed: 20305656]
8. Cohen PT. J Cell Sci. 2002; 115:241–56. [PubMed: 11839776]
9. Bollen M. Trends Biochem Sci. 2001; 26:426–31. [PubMed: 11440854]
10. Hurley TD, Yang J, Zhang L, Goodwin KD, Zou Q, Cortese M, Dunker AK, DePaoli-Roach AA. J
Biol Chem. 2007; 282:28874–83. [PubMed: 17636256]
11. Terrak M, Kerff F, Langsetmo K, Tao T, Dominguez R. Nature. 2004; 429:780–4. [PubMed:
15164081]
12. Kelker MS, Page R, Peti W. J Mol Biol. 2009; 385:11–21. [PubMed: 18992256]
13. Dancheck B, Nairn AC, Peti W. Biochemistry. 2008; 47:12346–56. [PubMed: 18954090]
14. Marsh JA, Dancheck B, Ragusa MJ, Allaire M, Forman-Kay JD, Peti W. Structure. 2010;
18:1094–1103. [PubMed: 20826336]
15. Toth A, Kiss E, Herberg FW, Gergely P, Hartshorne DJ, Erdodi F. Eur J Biochem. 2000;
267:1687–97. [PubMed: 10712600]
16. Peti W, Page R. Protein Expr Purif. 2007; 51:1–10. [PubMed: 16904906]
17. Sattler J, Schleucher J, Griesinger C. Progress in NMR Spectroscopy. 1999; 34:93–158.
18. Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Protein Sci. 2006; 15:2795–804. [PubMed:
17088319]
19. Zhang H, Neal S, Wishart DS. J Biomol NMR. 2003; 25:173–95. [PubMed: 12652131]
20. Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T,
Forman-Kay JD, Kay LE. Biochemistry. 1994; 33:5984–6003. [PubMed: 7514039]
Pinheiro et al. Page 11













21. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. J Biomol NMR. 1995; 6:277–93.
[PubMed: 8520220]
22. Johnson BA. Methods Mol Biol. 2004; 278:313–52. [PubMed: 15318002]
23. Ruckert M, Otting G. J Am Chem Soc. 2000; 122:7793–7797.
24. Permi P, Rosevear PR, Annila A. J Biomol NMR. 2000; 17:43–54. [PubMed: 10909865]
25. Ottiger M, Delaglio F, Bax A. J Magn Reson. 1998; 131:373–8. [PubMed: 9571116]
26. Meiler J, Peti W, Griesinger C. J Biomol NMR. 2000; 17:283–94. [PubMed: 11014592]
27. Zweckstetter M. Nat Protoc. 2008; 3:679–90. [PubMed: 18388951]
28. Huang HB, Horiuchi A, Watanabe T, Shih SR, Tsay HJ, Li HC, Greengard P, Nairn AC. J Biol
Chem. 1999; 274:7870–8. [PubMed: 10075680]
29. Kim YM, Watanabe T, Allen PB, Lee SJ, Greengard P, Nairn AC, Kwon YG. J Biol Chem. 2003;
278:13819–28. [PubMed: 12574161]
30. Choy WY, Forman-Kay JD. J Mol Biol. 2001; 308:1011–32. [PubMed: 11352588]
31. Marsh JA, Neale C, Jack FE, Choy WY, Lee AY, Crowhurst KA, Forman-Kay JD. J Mol Biol.
2007; 367:1494–510. [PubMed: 17320108]
32. Marsh JA, Forman-Kay JD. J Mol Biol. 2009; 391:359–74. [PubMed: 19501099]
33. Marsh JA, Baker JM, Tollinger M, Forman-Kay JD. J Am Chem Soc. 2008; 130:7804–5.
[PubMed: 18512919]
34. Kelley LA, Gardner SP, Sutcliffe MJ. Protein Eng. 1996; 9:1063–5. [PubMed: 8961360]
35. Feldman HJ, Hogue CW. Proteins. 2000; 39:112–31. [PubMed: 10737933]
36. Mohana-Borges R, Goto NK, Kroon GJ, Dyson HJ, Wright PE. J Mol Biol. 2004; 340:1131–42.
[PubMed: 15236972]
37. Cornilescu G, Marquardt JL, Ottiger M, Bax A. J Am Chem Soc. 1998; 120:6836–6837.
38. Frishman D, Argos P. Proteins. 1995; 23:566–79. [PubMed: 8749853]
39. Bernado P, Bertoncini CW, Griesinger C, Zweckstetter M, Blackledge M. J Am Chem Soc. 2005;
127:17968–9. [PubMed: 16366524]
40. Huang HB, Chen YC, Lee TT, Huang YC, Liu HT, Liu CK, Tsay HJ, Lin TH. Proteins. 2007;
68:779–88. [PubMed: 17510962]
41. Huang HB, Chen YC, Tsai LH, Wang H, Lin FM, Horiuchi A, Greengard P, Nairn AC, Shiao MS,
Lin TH. J Biomol NMR. 2000; 17:359–60. [PubMed: 11014604]
42. Lin TH, Huang YC, Chin ML, Chen YC, Jeng HH, Lin FM, Shiao MS, Horiuchi A, Greengard P,
Nairn AC, Huang HB. J Biomol NMR. 2004; 28:413–4. [PubMed: 14872138]
43. Dosztanyi Z, Csizmok V, Tompa P, Simon I. Bioinformatics. 2005; 21:3433–4. [PubMed:
15955779]
44. Shoemaker BA, Portman JJ, Wolynes PG. Proc Natl Acad Sci U S A. 2000; 97:8868–73.
[PubMed: 10908673]
45. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. Embo J. 1997; 16:1876–87.
[PubMed: 9155014]
Pinheiro et al. Page 12














Crystal structure of the MYPT1:PP1 complex (PDBid: 1S70). (A) PP1 is shown as a surface
representation (light gray). The two Mn2+ ions present in the active site of PP1 are
highlighted in light blue. MYPT1 is shown as a cartoon representation, and colored to
illustrate the different constructs used in this study (see also Figure 1C): MYPT11-41 (red);
MYPT1-98 (red and purple) and MYPT11-299 (red, purple and blue). MYPT1 ankyrin repeats
are numbered 1 to 8; all ankyrin –repeats make contacts with PP1; N-, C-terminal and
MyPhoNE PP1-binding motif residues are annotated. (B) Same as A rotated by 90°. The
RVxF motif is annotated. (C) 1D representation of MYPT1: MYPT11-299, MYPT11-98 and
MYPT11-41. Ankyrin repeats are represented by gray boxes and numbered according to A.
The MYPT1-specific RvXF motif (35 KVKF38) is highlighted in black, N-terminal adjacent
to the first ankyrin repeat. The N-terminal transient helix, part of the MYPT1 disordered
region, is depicted in blue. Color-coded bars correlate directly with coloring of MYPT1 in
Figure 1A,B.
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(A) Secondary structure propensity scores, (B) experimental R2 relaxation rates, and (C)
heteronuclear 15N[1H]-NOE measurements demonstrate the two-domain behavior of
MYPT11-98 in solution. Cartoon representations above the SSP scores indicate presence of
secondary structure based on the MYPT1:PP1 complex structure. A dashed line separates
the two different regions of MYPT11-98, the N-terminal flexible region and the C-terminal
folded ankyrin-repeat region, which constitute the MYPT1 PP1-binding domain. An element
of transient structure and reduced backbone motion within residues 5-17 in the N-terminal
disordered region can be readily identified by SSP scores greater than ~0.2, elevated R2 rates
and 15N[1H]-NOE values. This transient helix is colored in blue, which differentiates it from
the fully populated α-helices of the ankyrin-repeat domain, colored in gray.
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(A) Experimental DNH RDCs measured for MYPT11-98 in 5% C8E5/1-Octanol alignment
medium. (B) Comparison of experimentally derived DNH RDCs for MYPT11-98 free in
solution (black) and calculated DNH for MYPT11-98 in its complex-bound conformation
(gray). Secondary structural elements, based on the MYPT1:PP1 complex crystal structure,
are indicated using cartoon representations.
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(A) Secondary structure content of calculated ensembles for MYPT11-98. Lines represent the
α-helix populations (green, populations in the α (red), and β (blue) regions of the
Ramachandran diagram (regions defined in32). Error bars show the standard deviations
between the six independently calculated ensembles. (B) Agreement between experimental
RDCs (blue) and RDCs calculated from the ensemble model (red) and a 5000-structure
statistical coil model for residues 1-40 appended to the folded structure for 41-98 (green;
details described in methods).
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The three most significantly populated clusters (A - 29%, B - 19%, C - 16%) and their
fractional contact plots for MYPT11-98. Fractional contact plots represent the fractional
formation of contacts between pairs of residues, with a contact being defined as any two
heavy atoms being within 10 Å of each other. The upper halves of the contact plots show
contacts present in the clusters while the lower halves show contacts present in PP1-bound
MYPT1. Structures are colored as follows: ankyrin-repeat domain (residues 41-98) – blue;
residues 1-20 red; residues 21-40 green.
Pinheiro et al. Page 17

























Pinheiro et al. Page 18
Table 1
List of experimental restraints used in the MYPT1 ensemble model calculations and their agreement with the
ensemble-predicted properties.
Restraint type Number of restraints Ensemble agreementa
13Cα chemical shifts 35 0.18 ppm
13Cβ chemical shifts 34 0.22 ppm
13C′ chemical shifts 35 0.26 ppm
1Hα chemical shifts 32 0.043 ppm
1HN chemical shifts 33 0.11 ppm
15N chemical shifts 33 0.46 ppm
1H-15N RDCs 87 3.7 Hz
Hydrodynamic radius 1 0.92 Å
15N R2 32 0.77
a
Ensemble agreement is the root mean square deviation between experimentally determined and ensemble-predicted values, except for 15N R2
restraints where it is the Pearson correlation between experimental values and local contact density, as previously defined32.
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